106 related articles for article (PubMed ID: 18090928)
1. Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients.
Koshkina NV; Kleinerman ES; Li G; Zhao CC; Wei Q; Sturgis EM
J Pediatr Hematol Oncol; 2007 Dec; 29(12):815-21. PubMed ID: 18090928
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
Zhou RM; Wang N; Chen ZF; Duan YN; Sun DL; Li Y
J Gastroenterol Hepatol; 2010 Mar; 25(3):555-61. PubMed ID: 20074157
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma.
Liu Y; He Z; Feng D; Shi G; Gao R; Wu X; Song W; Yuan W
DNA Cell Biol; 2011 Dec; 30(12):1051-5. PubMed ID: 21612409
[TBL] [Abstract][Full Text] [Related]
4. Association of FAS -1377 G>A and FAS -670 A>G functional polymorphisms of FAS gene of cell death pathway with recurrent early pregnancy loss risk.
Nair RR; Khanna A; Singh K
J Reprod Immunol; 2012 Mar; 93(2):114-8. PubMed ID: 22386066
[TBL] [Abstract][Full Text] [Related]
5. [Correlation of XPC Ala499Val and Lys939Gln polymorphisms to risks of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].
Zhou RM; Li Y; Wang N; Zhang XJ; Dong XJ; Guo W
Ai Zheng; 2006 Sep; 25(9):1113-9. PubMed ID: 16965652
[TBL] [Abstract][Full Text] [Related]
6. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia.
Farre L; Bittencourt AL; Silva-Santos G; Almeida A; Silva AC; Decanine D; Soares GM; Alcantara LC; Van Dooren S; Galvão-Castro B; Vandamme AM; Van Weyenbergh J
J Leukoc Biol; 2008 Jan; 83(1):220-2. PubMed ID: 17962369
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck.
Zhang Z; Wang LE; Sturgis EM; El-Naggar AK; Hong WK; Amos CI; Spitz MR; Wei Q
Clin Cancer Res; 2006 Sep; 12(18):5596-602. PubMed ID: 17000697
[TBL] [Abstract][Full Text] [Related]
8. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies.
Zhang Z; Xue H; Gong W; Wang M; Yuan L; Han S; Zhang Z
Carcinogenesis; 2009 Mar; 30(3):487-93. PubMed ID: 19168581
[TBL] [Abstract][Full Text] [Related]
9. CD86 + 1057G/A polymorphism and susceptibility to osteosarcoma.
Wang W; Song H; Liu J; Song B; Cao X
DNA Cell Biol; 2011 Nov; 30(11):925-9. PubMed ID: 21563968
[TBL] [Abstract][Full Text] [Related]
10. Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules.
Arasteh JM; Sarvestani EK; Aflaki E; Amirghofran Z
Immunol Invest; 2010; 39(1):27-38. PubMed ID: 20064083
[TBL] [Abstract][Full Text] [Related]
11. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus.
Kanemitsu S; Ihara K; Saifddin A; Otsuka T; Takeuchi T; Nagayama J; Kuwano M; Hara T
J Rheumatol; 2002 Jun; 29(6):1183-8. PubMed ID: 12064832
[TBL] [Abstract][Full Text] [Related]
12. Fas single nucleotide polymorphisms and risk of thyroid and salivary gland carcinomas: a case-control analysis.
Ho T; Li G; Zhao C; Zheng R; Wei Q; Sturgis EM
Head Neck; 2008 Mar; 30(3):297-305. PubMed ID: 17657791
[TBL] [Abstract][Full Text] [Related]
13. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
[TBL] [Abstract][Full Text] [Related]
14. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis.
Liakouli V; Manetti M; Pacini A; Tolusso B; Fatini C; Toscano A; Cipriani P; Guiducci S; Bazzichi L; Codullo V; Ruocco L; Dell'orso L; Carubbi F; Marrelli A; Abbate R; Bombardieri S; Ferraccioli G; Montecucco C; Valentini G; Matucci-Cerinic M; Ibba-Manneschi L; Giacomelli R
Ann Rheum Dis; 2009 Apr; 68(4):584-90. PubMed ID: 18445624
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 gene polymorphism of exon 1(+49 A/G) in Turkish systemic lupus erythematosus patients.
Ulker M; Yazisiz V; Sallakci N; Avci AB; Sanlioglu S; Yegin O; Terzioglu E
Int J Immunogenet; 2009 Aug; 36(4):245-50. PubMed ID: 19602000
[TBL] [Abstract][Full Text] [Related]
16. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
[TBL] [Abstract][Full Text] [Related]
17. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
18. Fas promoter region gene polymorphism is associated with an increased risk for myocardial infarction.
Hanasaki H; Takemura Y; Fukuo K; Ohishi M; Onishi M; Yasuda O; Katsuya T; Awata N; Kato N; Ogihara T; Rakugi H
Hypertens Res; 2009 Apr; 32(4):261-4. PubMed ID: 19262492
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
20. Caspase 9 promoter polymorphisms and risk of primary lung cancer.
Park JY; Park JM; Jang JS; Choi JE; Kim KM; Cha SI; Kim CH; Kang YM; Lee WK; Kam S; Park RW; Kim IS; Lee JT; Jung TH
Hum Mol Genet; 2006 Jun; 15(12):1963-71. PubMed ID: 16687442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
